DGEAF
DIAGEO PLC
$19.75
+0.77%
No data for this timeframe.
Vol
SEC Reports4
Recent Activity
Jun 1, 2026
SEC
This 6-K filing is a batch of routine administrative announcements for Diageo during May 2026, including total voting ri
6-K — Impact 2/10
May 6, 2026
SEC
Diageo's Q3 fiscal 2026 trading statement shows organic net sales growth of just 0.3% for the quarter, with a 9.4% organ
6-K — Impact 6/10
Apr 17, 2026
SEC
Artisan Partners Limited Partnership crossed the 5% threshold in Diageo PLC, holding 5.027% of voting rights through dir
6-K — Impact 3/10
Analyst Ratings
10Strong Buy
12Buy
7Hold
2Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 20, 2020 | RBC Capital | DOWNGRADE | Outperform → Sector Perform |
Latest Reports
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
4 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 1 mixed, 2 neutral. Avg impact: 4.3/10.
NEUTRAL
6-K
2/10
This 6-K filing is a batch of routine administrative announcements for Diageo during May 2026, inclu
Jun 1, 2026
BEARISH
6-K
6/10
Diageo's Q3 fiscal 2026 trading statement shows organic net sales growth of just 0.3% for the quarte
May 6, 2026
NEUTRAL
6-K
3/10
Artisan Partners Limited Partnership crossed the 5% threshold in Diageo PLC, holding 5.027% of votin
Apr 17, 2026
MIXED
6-K
6/10
Diageo PLC filed a 6-K disclosing several routine matters including director shareholdings, a debt p
Apr 1, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Apr 2020): 71% buy across 31 analysts — 10 strong buy, 12 buy, 7 hold, 2 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-03-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $4.3B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $19.6B | -3.1% | — |
| Next FY 2027-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $19.4B | -1.1% | — |
1 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 20, 2020 | RBC Capital | DOWNGRADE | Outperform | Sector Perform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 10 | 12 | 7 | 2 | 0 | 71% | |
| May 1, 2026 | 9 | 12 | 7 | 3 | 0 | 68% | |
| Apr 1, 2026 | 9 | 12 | 7 | 3 | 0 | 68% | |
| Mar 1, 2026 | 9 | 12 | 7 | 3 | 0 | 68% | |
| Feb 1, 2026 | 9 | 11 | 8 | 3 | 0 | 65% | |
| Jan 1, 2026 | 9 | 10 | 9 | 3 | 0 | 61% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.